Vitiligo - Macular DepigmentationDermabrasionNCT02660320
Comparison of the Efficacy of Micro-holes vs. Laser-assisted Dermabrasion, for Repigmenting in Vitiligo Skin
A study testing Dermabrasion in people with Vitiligo - Macular Depigmentation, run by Centre Hospitalier Universitaire de Nice at 3 sites in France.
Trial summary
Principal objective: To compare the efficacy of laser-assisted dermabrasion + autologous epidermal cells suspension grafting versus dermabrasion using micro-needling technique + autologous epidermal cells suspension grafting and dermabrasion using micro-needling technique + placebo suspension grafting in stable… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Vitiligo - Macular Depigmentation
- What is being tested?
- Dermabrasion
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 5 participants
- Where
- 3 sitesFrance
- Study dates
- Feb 2016to Mar 2019
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Men and women aged over 18 years old with a diagnosis of non-segmental lesions that has been stable over three months
- The minimum distance between the normal pigmented skin and the test area should preferably be at least 0.5 cm.
- For each patient the lesions are located on the same area (either chest, back, legs or arms)
- The lesion area must be: 2cm2 < lesion<50cm2
- Treatment resistant areas (failure of at least one medical procedure topical tacrolimus or topical steroids for 6 months).
- Absence of infected lesion
- Lesions stable for at least one year
Who cannot join
- Hypersensibility to local anaesthetics or one of the components of the device (trypsin, hyaluronic acid)
- Indication against biopsies
- Patient with a history of melanoma
- Positive serology (ongoing serious systemic disease, herpes, HIV, hepatitis B and C)
- History of keloidal scars and presence of Koebner's phenomenon (type 1 and type 2b)
- Infected lesion
Show all 10Show fewer
- Patient with concomitant photosensitizing treatment
- Age <18 years
- Major deprived of their freedom by administrative or legal decision, or being the subject of a legal protection measure, or out of state to express their consent
- Pregnant,delivering or lactating patients. For the women childbearing potential, a urinary pregnancy test will be done and effective contraception will be expected.
Trial locations and contacts
3 sites in 1 country.
France3 sites
CHU de Bordeaux
Bordeaux, 33 000
CHU de Nice
Nice, Alpes-Maritimes, 06200
CH Creteil
Paris, Île-de-France Region
About this study
Principal objective: To compare the efficacy of laser-assisted dermabrasion + autologous epidermal cells suspension grafting versus dermabrasion using micro-needling technique + autologous epidermal cells suspension grafting and dermabrasion using micro-needling technique + placebo suspension grafting in stable vitiligo.
A total of 10 patients with stable non-segmental vitiligo will be included in the ITT population.
Read more
In each patient, three separate test areas will be selected in the same part of the body.
One area will be pre-treated with dermaroller and receive the hyaluronic acid suspension alone and the two others will receive the epidermal cell suspension in hyaluronic acid after pre-treatment either with dermaroller or laser-assisted dermabrasion, each patient being his own control.
Targeted phototherapy with excimer lamp (308 nMm) will be applied on all test areas 1 week after cell grafting.
Read the detailed description
Condition Stable lesion of Vitiligo of adulthood
Background Laser-assisted dermabrasion is the gold standard for preparing the grafting bed of epidermal suspension but it requires a technical platform and a trained physician. Side effects are not uncommon. We have demonstrated in an ex vivo study that micro-needles create holes in the epidermis allowing cells to reach the lower layers of the epidermis. We hypothesize that the use of micro-needles could be an effective and easy technique for preparing the grafting bed for epidermal suspensions.
Objectives Principal objective: To compare the efficacy of laser-assisted dermabrasion + autologous epidermal cells suspension grafting versus dermabrasion using micro-needling technique + autologous epidermal cells suspension grafting and dermabrasion using micro-needling technique + placebo suspension grafting in stable vitiligo.
The secondary objectives are
- To evaluate and compare the tolerability of the distinct procedures
- To evaluate the global satisfaction of patient and the willingness to reproduce the procedure for treating other areas
- To evaluate the contrast between treated skin and perilesional area
Methods Prospective, multicentre, randomized, controlled, blind assessor trial.
Inclusion criteria
- Men and women aged over 18 years old with a diagnosis of non-segmental lesions that has been stable over three months
- The minimum distance between the normal pigmented skin and the test area should preferably be at least 0.5 cm.
- For each patient the lesions are located on the same area (either chest, back, legs or arms)
- The lesion area must be: 2cm2 < lesion<50cm2
- Treatment resistant areas (failure of at least one medical procedure topical tacrolimus or topical steroids for 6 months).
- Absence of infected lesion
- Lesions stable for at least one year
Exclusion criteria Hypersensibility to local anaesthetics or one of the components of the device (trypsin, hyaluronic acid)
- Indication against biopsies
- Patient with a history of melanoma
- Positive serology (ongoing serious systemic disease, herpes, HIV, hepatitis B and C)
- History of keloidal scars and presence of Koebner's phenomenon (type 1 and type 2b)
- Infected lesion
- Patient with concomitant photosensitizing treatment
- Age <18 years
- Major deprived of their freedom by administrative or legal decision, or being the subject of a legal protection measure, or out of state to express their consent
- Pregnant,delivering or lactating patients. For the women childbearing potential, a urinary pregnancy test will be done and effective contraception will be expected.
Interventions After inclusion visit, randomization will occur during visit 1, the day of the surgery to determine which lesion will be treated by dermaroller+hyaluronic acid, dermaroller+VITICELL® or laser-assisted dermabrasion+VITICELL®.
Dermabrasion procedures:
Three test areas will be selected on the same part of body. Each lesion will respectively treated by:
- Dermaroller + hyaluronic acid + phototherapy
- Dermaroller + VITICELL® + phototherapy
- Laser + VITICELL® + phototherapy
Dermabrasion using laser:
To prepare the graft recipient site, the upper layer of epidermis is removed by superficial dermabrasion using Erbium or CO2 ablative laser. The test area is ready to receive suspension cells when the dermis will appeared. The cells suspension will be applied on the wound.
Dermabrasion using dermaroller: The dermaroller is applied on the treated areas, this dermabrasion technique is based on micro holes performed using 540 micro needles (200µm depth) which should allow the penetration of the suspension cells or hyaluronic acid alone. Twelve passages will be performed on the treated area in order to achieve 60% of coverage.
VITICELL® treated area:
A small sample of skin (biopsy) will be collected from the gluteal area. The biopsy will be measured 4 cm2 (2x2cm) systematically. While the investigator is preparing the areas to be treated, the skin will be placed into the VITICELL® kit by other heath professional. The VITICELL® kit will transform the patient's collected skin into a cellular suspension. The suspension of epidermal cells is then applied (100µL per cm2) onto the 2 selected lesions/areas after dermabrasion with dermaroller or laser.
Hyaluronic acid with PBS treated area:
The suspension of hyaluronic acid is applied (100 µL/cm2) onto the selected lesion after dermabrasion with dermaroller.
Following the surgery, the treated area and biopsy site will be covered with a dressing and must be protected from direct sun and physical impact for a period of 6 -7days. After this period the dressing will be removed.
Phototherapy:
The phototherapy will begin a week after cells grafting and will be used 2 times a week for all the treatment duration.
The ultraviolet (UV) spectrum has been used on test areas. These different wavelength will promote melanogenesis and melanocyte proliferation on graft side.
- Conditions
- Vitiligo - Macular Depigmentation
- Being tested
- Dermabrasion, Laser placebo
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
DermabrasionDevice
Preparing the graft bed before epidermal cell suspension The epidermis can be removed using ablative CO2 or Erbium laser. We will assess the efficacy of using instead micro-needles to create micro-holes that will allow the melanocytes to reach the lower layers of the epidermis and thus repigment the lesional skin.
Laser placeboDevice
The epidermis can be removed using ablative CO2 or Erbium laser. We will assess the efficacy of using instead micro-needles to create micro-holes that will allow the melanocytes to reach the lower layers of the epidermis and thus repigment the lesional skin.
| Study group | Role | What they receive |
|---|---|---|
| Dermabrasion | Active comparator | Dermabrasion using dermaroller: The dermaroller is applied on the treated areas, this dermabrasion technique is based on micro holes performed using 540 micro needles (200µm depth) which should allow the penetration of the suspension cells or hyaluronic acid alone. Twelve passages will be performed on the treated area in order to achieve 60% of coverage. Receives: Device: Dermabrasion |
| Laser | Placebo comparator | To prepare the graft recipient site, the upper layer of epidermis is removed by superficial dermabrasion using Erbium or CO2 ablative laser. The test area is ready to receive suspension cells when the dermis will appeared. The cells suspension will be applied on the wound. Receives: Device: Laser placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Rate of repigmentation lesions
Rate of repigmentation lesions at 3 months
Measured: at 3 months
Secondary outcomes (3)
Global satisfaction expressed by the patient
Global satisfaction expressed by the patient per treated area at the end of the treatment
Measured: at 3 months
EVA scale
Pain expressed by the patient during the procedure (EVA scale)
Measured: During the procedure
-Contrast between treated and perilesional area (Nottingham scale)
Contrast between treated and perilesional area (Nottingham scale)
Measured: at 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Jan 2016 (estimated)
- Study startFeb 2016
- Primary completionOct 2018
- Study completionMar 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Vitiligo - Macular DepigmentationStudies of the same condition, open and under way.
- More trials run by Centre Hospitalier Universitaire de NiceThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 5 participants (actual)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier Universitaire de Nice
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Passeron Thierry, PhD, Principal investigator, Dermatology, CHU de Nice
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02660320
- Sponsor's protocol ID
- 15-PP-09
- Acronym
- Dermabrasion
- Status last verified
- Jan 2018
- First submitted
- 4 Jan 2016
- Last updated
- 31 Aug 2022
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 31 Aug 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of the Efficacy of Micro-holes vs. Laser-assisted Dermabrasion, for Repigmenting in Vitiligo Skin
- ClinicalTrials.gov ID
- NCT02660320
- Acronym / sponsor ID
- Dermabrasion / 15-PP-09
- Conditions
- Vitiligo - Macular Depigmentation
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 5 participants (actual)
- Lead sponsor
- Centre Hospitalier Universitaire de NiceUniversity, hospital or other
- Study start
- Feb 2016 (actual)
- Primary completion
- Oct 2018 (actual)
- Study completion
- Mar 2019 (actual)
- First posted
- 21 Jan 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Principal objective: To compare the efficacy of laser-assisted dermabrasion + autologous epidermal cells suspension grafting versus dermabrasion using micro-needling technique + autologous epidermal cells suspension grafting and dermabrasion using micro-needling technique + placebo suspension grafting in stable vitiligo.
A total of 10 patients with stable non-segmental vitiligo will be included in the ITT population.
In each patient, three separate test areas will be selected in the same part of the body.
One area will be pre-treated with dermaroller and receive the hyaluronic acid suspension alone and the two others will receive the epidermal cell suspension in hyaluronic acid after pre-treatment either with dermaroller or laser-assisted dermabrasion, each patient being his own control.
Targeted phototherapy with excimer lamp (308 nMm) will be applied on all test areas 1 week after cell grafting.
Detailed description
Condition Stable lesion of Vitiligo of adulthood
Background Laser-assisted dermabrasion is the gold standard for preparing the grafting bed of epidermal suspension but it requires a technical platform and a trained physician. Side effects are not uncommon. We have demonstrated in an ex vivo study that micro-needles create holes in the epidermis allowing cells to reach the lower layers of the epidermis. We hypothesize that the use of micro-needles could be an effective and easy technique for preparing the grafting bed for epidermal suspensions.
Objectives Principal objective: To compare the efficacy of laser-assisted dermabrasion + autologous epidermal cells suspension grafting versus dermabrasion using micro-needling technique + autologous epidermal cells suspension grafting and dermabrasion using micro-needling technique + placebo suspension grafting in stable vitiligo.
The secondary objectives are
- To evaluate and compare the tolerability of the distinct procedures
- To evaluate the global satisfaction of patient and the willingness to reproduce the procedure for treating other areas
- To evaluate the contrast between treated skin and perilesional area
Methods Prospective, multicentre, randomized, controlled, blind assessor trial.
Inclusion criteria
- Men and women aged over 18 years old with a diagnosis of non-segmental lesions that has been stable over three months
- The minimum distance between the normal pigmented skin and the test area should preferably be at least 0.5 cm.
- For each patient the lesions are located on the same area (either chest, back, legs or arms)
- The lesion area must be: 2cm2 < lesion<50cm2
- Treatment resistant areas (failure of at least one medical procedure topical tacrolimus or topical steroids for 6 months).
- Absence of infected lesion
- Lesions stable for at least one year
Exclusion criteria Hypersensibility to local anaesthetics or one of the components of the device (trypsin, hyaluronic acid)
- Indication against biopsies
- Patient with a history of melanoma
- Positive serology (ongoing serious systemic disease, herpes, HIV, hepatitis B and C)
- History of keloidal scars and presence of Koebner's phenomenon (type 1 and type 2b)
- Infected lesion
- Patient with concomitant photosensitizing treatment
- Age <18 years
- Major deprived of their freedom by administrative or legal decision, or being the subject of a legal protection measure, or out of state to express their consent
- Pregnant,delivering or lactating patients. For the women childbearing potential, a urinary pregnancy test will be done and effective contraception will be expected.
Interventions After inclusion visit, randomization will occur during visit 1, the day of the surgery to determine which lesion will be treated by dermaroller+hyaluronic acid, dermaroller+VITICELL® or laser-assisted dermabrasion+VITICELL®.
Dermabrasion procedures:
Three test areas will be selected on the same part of body. Each lesion will respectively treated by:
- Dermaroller + hyaluronic acid + phototherapy
- Dermaroller + VITICELL® + phototherapy
- Laser + VITICELL® + phototherapy
Dermabrasion using laser:
To prepare the graft recipient site, the upper layer of epidermis is removed by superficial dermabrasion using Erbium or CO2 ablative laser. The test area is ready to receive suspension cells when the dermis will appeared. The cells suspension will be applied on the wound.
Dermabrasion using dermaroller: The dermaroller is applied on the treated areas, this dermabrasion technique is based on micro holes performed using 540 micro needles (200µm depth) which should allow the penetration of the suspension cells or hyaluronic acid alone. Twelve passages will be performed on the treated area in order to achieve 60% of coverage.
VITICELL® treated area:
A small sample of skin (biopsy) will be collected from the gluteal area. The biopsy will be measured 4 cm2 (2x2cm) systematically. While the investigator is preparing the areas to be treated, the skin will be placed into the VITICELL® kit by other heath professional. The VITICELL® kit will transform the patient's collected skin into a cellular suspension. The suspension of epidermal cells is then applied (100µL per cm2) onto the 2 selected lesions/areas after dermabrasion with dermaroller or laser.
Hyaluronic acid with PBS treated area:
The suspension of hyaluronic acid is applied (100 µL/cm2) onto the selected lesion after dermabrasion with dermaroller.
Following the surgery, the treated area and biopsy site will be covered with a dressing and must be protected from direct sun and physical impact for a period of 6 -7days. After this period the dressing will be removed.
Phototherapy:
The phototherapy will begin a week after cells grafting and will be used 2 times a week for all the treatment duration.
The ultraviolet (UV) spectrum has been used on test areas. These different wavelength will promote melanogenesis and melanocyte proliferation on graft side.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Dermabrasion | Active comparator | Device: DermabrasionDermabrasion using dermaroller: The dermaroller is applied on the treated areas, this dermabrasion technique is based on micro holes performed using 540 micro needles (200µm depth) which should allow the penetration of the suspension cells or hyaluronic acid alone. Twelve passages will be performed on the treated area in order to achieve 60% of coverage. |
| Laser | Placebo comparator | Device: Laser placeboTo prepare the graft recipient site, the upper layer of epidermis is removed by superficial dermabrasion using Erbium or CO2 ablative laser. The test area is ready to receive suspension cells when the dermis will appeared. The cells suspension will be applied on the wound. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Men and women aged over 18 years old with a diagnosis of non-segmental lesions that has been stable over three months
- The minimum distance between the normal pigmented skin and the test area should preferably be at least 0.5 cm.
- For each patient the lesions are located on the same area (either chest, back, legs or arms)
- The lesion area must be: 2cm2 < lesion<50cm2
- Treatment resistant areas (failure of at least one medical procedure topical tacrolimus or topical steroids for 6 months).
Key exclusion criteria (10 listed)
- Hypersensibility to local anaesthetics or one of the components of the device (trypsin, hyaluronic acid)
- Indication against biopsies
- Patient with a history of melanoma
- Positive serology (ongoing serious systemic disease, herpes, HIV, hepatitis B and C)
- History of keloidal scars and presence of Koebner's phenomenon (type 1 and type 2b)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| DermabrasionPreparing the graft bed before epidermal cell suspension The epidermis can be removed using ablative CO2 or Erbium laser. We will assess the efficacy of using instead micro-needles to create micro-holes that will allow the melanocytes to reach the lower layers of the epidermis and thus repigment the lesional skin. | Device | Dermabrasion |
| Laser placeboThe epidermis can be removed using ablative CO2 or Erbium laser. We will assess the efficacy of using instead micro-needles to create micro-holes that will allow the melanocytes to reach the lower layers of the epidermis and thus repigment the lesional skin. | Device | Laser |
Primary outcome
Rate of repigmentation lesions
Time frame: at 3 months
Rate of repigmentation lesions at 3 months
3 secondary outcomes
Global satisfaction expressed by the patient
Time frame: at 3 months
EVA scale
Time frame: During the procedure
-Contrast between treated and perilesional area (Nottingham scale)
Time frame: at 3 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Aug 2022.
- Individual participant dataSharing planned: Undecided
Related trials for Vitiligo - Macular Depigmentation
RecruitingObservational study
National Ophthalmic Genotyping and Phenotyping Network (eyeGENE (Registered Trademark)), Stage 3 - Expansion of DNA and Data Repositories for Rare Inherited Ophthalmic Diseases
Inherited Ophthalmic Diseases, Hypopigmentation Disorder
Not yet recruitingPhase 2
Comparative Study of Microneedling With Topical Minoxidil 5% ± NB-UVB in Stable Vitiligo"
Vitiligo - Macular Depigmentation
Enrolling by invitationEarly Phase 1
COMPARISON OF EFFICACY AND SAFETY OF NARROWBAND UVB WITH 0.1% TACROLIMUS VS NARROWBAND UVB WITH 0.005% CALCIPOTRIOL IN TREATMENT OF VITILIGO
Vitiligo - Macular Depigmentation, Tacrolimus
Not yet recruitingPhase 2
0.005% Latanoprost Gel for Nonsegmental Vitiligo
Vitiligo - Macular Depigmentation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Passeron Thierry, PhD principal investigator
Dermatology, CHU de Nice
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Dermabrasion in people with Vitiligo - Macular Depigmentation, run by Centre Hospitalier Universitaire de Nice at 3 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 31 Aug 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Rate of repigmentation lesions (time frame: at 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Aug 2022.